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Following the outbreak of autochthonous chikungunya fever
in humans in northern Italy, ﬁrst reported 3 years ago [1] we
have now witnessed two independent cases of autochthonous
transmission of dengue fever and two cases of chikungunya
fever in south-eastern France during September 2010. This
worrying trend has raised serious concern among the health
authorities, as Aedes albopictus, the Asian ‘tiger mosquito’, is
the most likely transmission vector of both viruses, and this
mosquito species is known to be spreading widely throughout
many regions of southern Europe. The two cases of dengue
fever occurred in patients (a 64-year-old male and an 18-year-
old male) living in Nice in the same neighbourhood and know-
ing each other. The two cases of chikungunya fever occurred
in 12-year-old female patients also living in the vicinity of each
other in Fre´jus, and attending the same high school. Both pre-
sented with high fever, headache, lombalgia and arthralgia.
These two patients lived in the same neighbourhood as the
unique laboratory-documented imported case of the county,
affecting a 7-year-old female patient returning from Asia. All
four cases resulted in mild, self-resolving infections.
The virological identiﬁcation of these four cases of arbo-
viral disease, with no travel history, and within the recorded
area of dissemination of A. albopictus, along the 180-km
region of the Mediterranean coast from Menton to Toulon
[2]: (i) demonstrates the ﬁrst cases of autochthonous trans-
mission of both viruses (dengue and chikungunya) in France;
(ii) implies that A. albopictus, which is resident in this region,
is the most likely competent vector for dengue virus (http://
www.sante-sports.gouv.fr/apparition-des-premiers-cas-auto
chtones-de-dengue-en-france-metropolitaine.html); and (iii)
raises important issues to be resolved in time for the next
‘mosquito season’, namely the adaptation of surveillance
systems and the implementation of countermeasures to limit
dispersal of the viruses and to limit the number of human
cases of dengue or chikungunya fever.
How alarmed should we be in Europe? Imported cases of
dengue and chikungunya fever have long been reported in
infected viraemic travellers [3] returning from tropical
regions where the viruses are endemic or transiently epi-
demic. Indeed, dengue virus ranks second only to the malar-
ial parasite as an agent of systemic febrile illness in travellers
to the tropics who are returning to Europe [4]. However,
during the past 5–10 years, the perceived risk of infection in
Europe, particularly with these two arboviruses, has
increased. This is because a competent mosquito vector was
not previously present at a sufﬁcient density in Europe to be
able to initiate and generate secondary human cases of
chikungunya or dengue fever among human populations.
With the establishment and ampliﬁcation of A. albopictus in
Europe, and these cases of dengue and chikungunya fever in
France, the perceived risk of epidemics caused by these
viruses or other emerging arboviruses has increased dramati-
cally. Consequently, in an attempt to prevent and monitor
the appearance of autochthonous cases, the French authori-
ties have elaborated a surveillance programme targeting both
viruses in returning travellers during the summer period of
vector activity (http://www.circulaires.gouv.fr/pdf/2010/05/cir_
31164.pdf). Among the 124 cases of laboratory-documented
imported cases of dengue fever since May 2010, most were
diagnosed in patients returning from the Caribbean (where
unprecedented numbers of cases were observed in 2010
(>70 000 in Martinique and Guadeloupe)) and Southeast Asia
(endemic dengue). The coincident seasonality of A. albopictus
activity in France and endemic or epidemic dengue virus
activity overseas was predicted to raise the likelihood of
emergence of autochthonous cases in France [5]. As we have
seen, two autochthonous cases of dengue fever have now
been documented in Nice. The even more recent autochtho-
nous cases of chikungunya fever in two children in Fre´jus
serve as an additional warning of the seriousness of the
incursion of A. albopictus (presumed to be the vector of both
of these viruses) into southern France. It is important to
note that this occurred despite the fact that only two
imported cases of chikungunya fever were recorded in trav-
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ellers returning to France in 2010. Probably, the very high
viral loads of clinically ill travellers returning to France [6]
constitute a major factor in the success of this virus.
Strategic surveillance and appropriate countermeasures
are urgently needed in anticipation of the possibility that
dengue and chikungunya viruses will survive in overwintering
mosquitoes or be re-introduced into French mosquitoes via
clinically ill travellers, leading to further cases, and possibly
even an epidemic of dengue or chikungunya fever during the
summer of 2011. The countermeasures should consist of: (i)
intensive surveillance at the medical, virological entomologi-
cal and environmental levels; (ii) consideration of the possi-
ble consequences for the blood transfusion service (based
on the experience of West Nile virus in North America);
(iii) education of the general public, and helpful guidance on
how to avoid mosquito bites; (iv) introduction of rapid diag-
nostic tests (RT-PCR and NS1 antigen detection) into the
public health system, to enable timely implementation
of entomological ﬁeld countermeasures; and (v) isolation of
viraemic patients, imported cases or autochthonous cases, as
preventive measures to limit the risk of dissemination to
active vectors.
In addition to all of these concerns, the detection of
autochthonous cases of dengue and chikungunya virus infec-
tions in southern France raises the issue of the safety of the
national blood transfusion system. For dengue virus world-
wide, there are only two published laboratory-documented
cases of infection related to transfusion [7,8], both resulting
in mild infections. For chikungunya virus, no cases linked with
transfusion have been published. Nevertheless, cases result-
ing from blood transfusion have almost certainly been signiﬁ-
cantly underestimated, as the documentation is extremely
difﬁcult to assess accurately in an endemic and epidemic
context [9]. These four French documented cases raise
speciﬁc questions concerning the screening procedures and
the appropriate timing of their implementation in the blood
bank system. Possible measures include nucleic acid testing
for dengue and chikungunya virus on blood samples collected
in regions where the presence of the tiger mosquito has
been conﬁrmed. However, whether or not this option is
employed, many practical questions need to be resolved, for
example: (i) the criteria that need to be fulﬁlled before we
initiate nucleic acid testing detection (epidemic threshold,
targeted area); (ii) how we should determine the at-risk
geographical area in term of blood bank system; and (iii)
whether we should accept and therefore act on the risk map
predictions for A. albopictus distribution in Europe produced
by the European Centre for Disease Prevention and Control
(http://ecdc.europa.eu/en/publications/Publications/0905_TER_
Development_of_Aedes_Albopictus_Risk_Maps.pdf) (Fig. 1).
The four very recent cases of autochthonous infection of
humans by emerging arboviruses in southern France serve as
an early warning of the potential dire consequences of the
establishment of A. albopictus in Europe. As the summer sea-
son is now almost over, the immediate likelihood of an epi-
demic arising in 2010 is very low. This does not mean we
should become complacent. Governments have a responsibil-
ity to act quickly and effectively. Additional measures that
might temporarily alleviate the problem should mimic those
implemented to reduce exposure to West Nile virus in
North America, i.e. rapid diagnosis of acutely infected
patients to enable the implementation of chemical and physi-
cal isolation from mosquitoes via the use of repellents and
bed-nets in the areas where the mosquitoes appear to be
established. However, in addition to implementation of these
‘classic’ measures, it is vital that appropriate measures should
FIG. 1. Dissemination of Aedes albopictus in
Europe and the Mediterranean countries (adapted
from http://ecdc.europa.eu/en/publications/
Publications/0905_TER_Development_of_Aedes_
Albopictus_Risk_Maps.pdf).
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be introduced and, if necessary, enforced to limit the
dissemination of the tiger mosquito throughout the at-risk
areas of Europe and ultimately to eradicate the mosquito.
Even though such a policy is currently considered to be
highly challenging, in terms of both cost and logistics, major
and innovative measures should be urgently planned and
introduced to effect a real reduction in terms of numbers
and dissemination. Failure to achieve this objective could
soon result in unimaginable levels of morbidity and mortality,
particularly when we consider the other emerging viruses
that might also be vectored by A. albopictus.
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